双氢青蒿素-哌喹与蒿甲醚-苯芴醇联合或不联合伯氨喹对间日疟复发疗效:系统综述与个体患者数据Meta分析
该系统综述与个体患者数据Meta分析纳入19项研究共2017例患者,比较双氢青蒿素-哌喹(DP)与蒿甲醚-苯芴醇(AL)联合或不联合伯氨喹(PQ)对间日疟复发风险的影响。结果显示第42天复发风险AL单药组44.0%显著高于DP单药组9.3%(AHR 12.63),哌喹剂量与复发率负相关,PQ联合可大幅降低复发风险。
要点
- 第42天复发风险AL单药组44.0%显著高于DP单药组9.3%(AHR 12.63,95%CI 6.40-24.92,p<0.001)。
- 哌喹每增加5 mg/kg,第42天复发AHR 0.63(95%CI 0.48-0.84,p=0.0013)。
- PQ联合显著降低第42天AL后复发(AHR 0.20)及第63天DP后复发(AHR 0.08)。
核心结论
- DP治疗后第42天间日疟复发风险显著低于AL,反映其更长的治疗后预防期,联合PQ可大幅降低复发风险。
- 延迟间日疟复发与血红蛋白小幅但显著的改善相关。
- 结果突显PQ根治及提供长效治疗后预防的血阶段抗疟药的益处。
研究设计与样本
- 系统综述与个体患者数据Meta分析,PROSPERO注册号CRD42016053310。
- 检索2000年1月1日至2018年1月31日发表的DP或AL治疗无并发症间日疟的临床疗效研究。
- 纳入19项研究共2017例患者,采用标准化方法汇总个体患者数据。
- 采用Cox回归分析按预先分析计划评估哌喹/苯芴醇mg/kg剂量、ACT方案及PQ对第7至42天间日疟复发率的影响。
主要发现
- 第42天复发风险AL单药组(384例)44.0%(95%CI 38.7-49.8)显著高于DP单药组(812例)9.3%(95%CI 7.1-12.2),AHR 12.63(95%CI 6.40-24.92),p<0.001。
- 哌喹每增加5 mg/kg,第42天复发AHR 0.63(95%CI 0.48-0.84,p=0.0013),第63天复发AHR 0.83(95%CI 0.73-0.94,p=0.0033)。
- 苯芴醇剂量与复发率无显著关联(每增加5 mg/kg,AHR 1.07,95%CI 0.99-1.16,p=0.0869)。
- 事后分析中,AL后出现症状性复发的患者,复发每延迟5天,平均血红蛋白增加0.13 g/dL(95%CI 0.01-0.26),p=0.0407。
- 联合PQ显著降低AL后第42天复发率(AHR 0.20,95%CI 0.10-0.41,p<0.001)及DP后第63天复发率(AHR 0.08,95%CI 0.01-0.70,p=0.0233)。
局限性
- 患者随访至63天或更短。
- 治疗分组为非随机化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We undertook a systematic review and individual patient data meta-analysis to compare the efficacies of dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine (PQ) on the risk of recurrent P. vivax. METHODS AND FINDINGS: Clinical efficacy studies of uncomplicated P. vivax treated with DP or AL and published between January 1, 2000, and January 31, 2018, were identified by conducting a systematic review registered with the International Prospective Register of Systematic Reviews (PROSPERO): CRD42016053310. Investigators of eligible studies were invited to contribute individual patient data that were pooled using standardised methodology. The effect of mg/kg dose of piperaquine/lumefantrine, ACT administered, and PQ on the rate of P. vivax recurrence between days 7 and 42 after starting treatment were investigated by Cox regression analyses according to an a priori analysis plan. Secondary outcomes were the risk of recurrence assessed on days 28 and 63. Nineteen studies enrolling 2,017 patients were included in the analysis. The risk of recurrent P. vivax at day 42 was significantly higher in the 384 patients treated with AL alone (44.0%, 95% confidence interval [CI] 38.7-49.8) compared with the 812 patients treated with DP alone (9.3%, 95% CI 7.1-12.2): adjusted hazard ratio (AHR) 12.63 (95% CI 6.40-24.92), p < 0.001. The rates of recurrence assessed at days 42 and 63 were associated inversely with the dose of piperaquine: AHRs (95% CI) for every 5-mg/kg increase 0.63 (0.48-0.84), p = 0.0013 and 0.83 (0.73-0.94), p = 0.0033, respectively. The dose of lumefantrine was not significantly associated with the rate of recurrence (1.07 for every 5-mg/kg increase, 95% CI 0.99-1.16, p = 0.0869). In a post hoc analysis, in patients with symptomatic recurrence after AL, the mean haemoglobin increased 0.13 g/dL (95% CI 0.01-0.26) for every 5 days that recurrence was delayed, p = 0.0407. Coadministration of PQ reduced substantially the rate of recurrence assessed at day 42 after AL (AHR = 0.20, 95% CI 0.10-0.41, p < 0.001) and at day 63 after DP (AHR = 0.08, 95% CI 0.01-0.70, p = 0.0233). Results were limited by follow-up of patients to 63 days or less and nonrandomised treatment groups. CONCLUSIONS: In this study, we observed the risk of P. vivax recurrence at day 42 to be significantly lower following treatment with DP compared with AL, reflecting the longer period of post-treatment prophylaxis; this risk was reduced substantially by coadministration with PQ. We found that delaying P. vivax recurrence was associated with a small but significant improvement in haemoglobin. These results highlight the benefits of PQ radical cure and also the provision of blood-stage antimalarial agents with prolonged post-treatment prophylaxis.
引用
- Commons RJ, Simpson JA, Thriemer K, et al. The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Med. 2019. PMID: 31584960. doi:10.1371/journal.pmed.1002928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。